Antibiotic-mediated chemoprotection enhances adaptation of E. coli PNP for herpes simplex virus-based glioma therapy

Human Gene Therapy

Volumn 16, Issue 3, 2005, Pages 339-347

  Bharara, Suman ^a   Sorscher, Eric J ^b,e   Gillespie, G Yancey ^a,c   Lindsey, J Russell ^d   Hong, Jeong S ^c,e   Curlee, Kimberly V ^e   Allan, Paula W ^f   Gadi, V K ^e   Alexander, Sherrie A ^e   Secrist III, John A ^f   Parker, William B ^f   Waud, William R ^f  

^a Kentucky   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f SOUTHERN RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHYLPURINE 2' DEOXYRIBOSIDE; ANTIBIOTIC AGENT; CYTOSINE DEAMINASE; HERPESVIRUS VECTOR; NUCLEOTIDE DERIVATIVE; PURINE NUCLEOSIDE PHOSPHORYLASE; UNCLASSIFIED DRUG;

ADAPTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BYSTANDER EFFECT; CANCER INHIBITION; CANCER REGRESSION; ESCHERICHIA COLI; GENE TRANSFER; GLIOMA; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; INTESTINE FLORA; MOUSE; NONHUMAN; SUICIDE GENE; VIRUS REPLICATION;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL LINE, TUMOR; ESCHERICHIA COLI; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENES, TRANSGENIC, SUICIDE; GENETIC VECTORS; GERM-FREE LIFE; GLIOMA; LENTIVIRUS; MICE; MICE, NUDE; PRODRUGS; PURINE NUCLEOSIDES; PURINE-NUCLEOSIDE PHOSPHORYLASE; SIMPLEXVIRUS; TIME FACTORS;

EID: 20144387887     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2005.16.339     Document Type: Article

References (32)

1. ANDREANSKY, S., HE, B., VANCOTT, J., MCGHEE, J., MARKERT, J.M., GILLESPIE, G.Y., ROIGMAN, B., and WHITLEY, R.J. (1998). Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 5, 121-130.
2. CURLEE, K.V., PARKER, W.B., and SORSCHER, E.J. (2004). Suicide gene therapy: Methods and reviews.. In C.J. Springer, ed., Methods in Molecular Medicine, Vol. 90. (Humana Press, Totowa, NJ) pp. 223-245.
3. DA COSTA, L.T., JEN, J., TONG-CHUAN, H., CHAN, T.A., KINZLER, K.W., and VOGELSTEIN, B. (1996). Converting cancer genes into killer genes. Proc. Natl. Acad. Sci. USA 93, 4192-4196.
4. DYKES, D.J., ABBOTT, B.J., MAYO, J.G., HARRISON, Jr., S.D., LASTER, Jr., W.R., SIMPSON-HERREN, L., and GRISWOLD, Jr., D.P. (1992). Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs. Contrib. Oncol. 42, 1-22.
5. EALICK, S.E., RULE, S.A., CARTER, D.C., GREENHOUGH, T.J., BABU, Y.S., COOK, W J., HABASH, J., HELLIWELL, J.R., STOECKLER, J.D., and PARKS, Jr., R.E. (1990). Three-dimensional structure of human erythrocytic purine nucleoside phosphorylase at 3.2 A resolution. J. Biol. Chem. 265(3), 1812-1820.
6. GADI, V.K., ALEXANDER, S.D., KUDLOW, J.E., ALLAN, P., PARKER, W.B., and SORSCHER, E.J. (2000). In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of tumor cells. Gene Ther. 7, 1738-1743.
7. GADI, V.K., ALEXANDER, S.D., WAUD, W.R., ALLAN, P.W., PARKER, W.B., and SORSCHER, E.J. (2003). A long-acting suicide gene toxin, 6-Methylpurine, inhibits slow growing tumors after a single administration. J. Pharmacol. Exp. Ther. 304, 1280-1284.
8. HASSAN, A.E., ABOU-ELKAIR, R.A., MONTGOMERY, J.A., and SECRIST III, J.A. (2000). Convenient syntheses of 6-methylpurine and related nucleosides. Nucl. Nucleic Acids 19, 1123-1134.
9. HUGHES B., PARKER, W.B., GADI, V.K., GARVER, R.I., and SORSCHER, E.J. (1995). Tumor specific killing with high bystander toxicity using the human tyrosinase promoter to express the E. coli PNP gene. Cancer Res. 55, 3339-3345.
10. HUGHES, B.W., KING, S.A., ALLAN, P.W., PARKER, W.B., and SORSCHER, E.J. (1998). Cell to cell contact is not required for bystander cell killing by E. coli purine nucleoside phosphorylase. J. Biol. Chem. 273(4), 2322-2328.
11. JENSEN, K.F., and NYGAARD., P. (1975). Purine nucleoside phosphorylase from Escherichia coli and Salmonella typhimurium. Purification and some properties. Eur. J. Biochem. 51, 253-265.
12. KROHNE, T.U., SHANKARA, S., GEISSLER, M., ROBERTS, B.L., WANDS, J.R., BLUM, H.E., and MOHY, L. (2001). Mechanisms of cell death induced by suicide genes encoding purine nucleoside phosphorylase and thymidine kinase in human hepatocellular carcinoma cells in vitro. Hepatology 34(3), 511-518.
13. LOCKETT, L.J., MOLLOY, P.L., RUSSELL, P.J., and BOTH, G.W. (1997). Relative efficiency of tumor cell killing in vitro by two enzyme-prodrug systems delivered by identical adenovirus vectors. Clin. Cancer Res. 3, 2075-2080.
14. MAO, C., COOK, W.J., ZHOU, M., KOSZALKA, G.W., KRENITSKY, T.A., and EALICK, S.E. (1997). The crystal structure of Escherichia coli purine nucleoside phosphorylase: A comparison with the human enzyme reveals a conserved topology. Structure 5, 1373-1383.
15. MARKERT, J.M., MEDLOCK, M.D., RABKIN, S.D., GILLESPIE, G.Y., TODO, T., HUNTER, W.D., PALMER, C.A., FEIGENBAUM, F., TORNATORE, C., TUFARO, F., and MARTUZA, R.L. (2000). Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: Results of a phase I trial. Gene Ther. 7, 867-874.
16. MARTINIELLO-WILKS, R., GARCIA-ARAGON, J., DAJA, M.M., RUSSELL, P., BOTH, G.W., MOLLOY, PL., LOCKETT, L.J., and RUSSELL. P.J. (1998). In vivo gene therapy for prostate cancer: Preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum. Gene Ther. 9, 1617-1626.
17. MOHR, L., SHANKARA, S., YOON, S.K., KROHNE, T.U., GEISSLER, M., ROBERTS, B., BLUM, H.E., and WANDS, J.R. (2000). Gene therapy of hepatocellular carcinoma in vitro and in vivo in nude mice by adenoviral transfer of the Escherichia coli purine nucleoside phosphorylase gene. Hepatology 31, 606-614.
18. NAMBA, H., IWADATE, Y., KAWAMURA, K. SAKEYAMA, S., and TAGAWA, M. (2001). Efficacy of the bystander effect in the herpes simplex virus thymidine kinase-mediated gene therapy is influenced by the expression of connexin43 in the target cells. Cancer Gene Ther. 8, 414-420.
19. NESTLER, U., HEINKELEIN, M., LUCKE, M., MEIXENSBERGER, J., SCHEURLEN, W., KRETSCHMER, A., and RETHWILM, A. (1997). Foamy virus vectors for suicide gene therapy. Gene Ther. 4, 1270-1277.
20. PARK, B. J., BROWN, C.K., HU, Y., ALEXANDER, H.R., HORTI, J., RAJE, J.S., FIGG, W.D., and BARTLETT, D.L. (1999). Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma. Hum. Gene Ther. 10, 889-898.
21. PARKER, J.N., GILLESPIE, G.Y., LOVE, C.E., RANDALL, S., WHITLEY, R.J., and MARKERT, J.M. (2000). Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc. Natl. Acad. Sci. USA 97, 2208-2213.
22. PARKER, W.B., KING, S.A., ALLAN, P.W., BENNETT Jr., L.L., SECRIST III, J.A., MONTGOMERY, J.A., GILBERT, K.S., WAUD, W.R., WELLS, A.H., GILLESPIE, G.Y., and SORSCHER, E.J. (1997). In vivo gene therapy of cancer with E. coli purine nucleoside phosphorylase. Hum. Gene Ther. 8, 1637-1644.
23. PARKER, W.B., ALLAN, P.W., SHADDIX, S.C., ROSE, L.M., SPEEGLE, H.F., GILLESPIE, G.Y., and BENNETT, Jr., L.L. (1998). Metabolism and metabolic actions of 6-methylpurine and 2-fluoroadenine in human cells. Biochem. Pharmacol. 55, 1673-1681.
24. PARKER W.B., ALLAN, P.W., HASSAN, A.E.A., SECRIST III, J.A., SORSCHER, E.J., and WAUD, W.R. (2003). Anti-tumor activity of 2-fluoro-2′- deoxyadenosine against tumors that express E. coli purine nucleoside phosphorylase. Cancer Gene Ther. 10, 23-29.
25. PUHLMANN, M., GNANT, M., BROWN, C.K., ALEXANDER, H.R., and BARTLETT, D.L. (1999). Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum. Gene Ther. 10, 649-657.
26. RAMPLING, R., CRUICKSHANK, G., PAPANASTASSIOU, V., NICOLL, J., HADLEY, D., BRENNAN, D., PETTY, R., MACLEAN, A., HARLAND, J., MCKIE E., MABBS, R., and BROWN, M. (2000). Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma. Gene Ther. 7, 859-866.
27. SECRIST III, J.A., PARKER, W.B., ALLAN, P.W., BENNETT, Jr., L.L., WAUD, W.R., TRUSS, J.W., FOWLER, A.T., MONTGOMERY, J.A., EALICK, S.E., WELLS, A.H., GILLESPIE, G.Y., GADI, V.K., and SORSCHER, E.J. (1999). Gene therapy of cancer: Activation of nucleoside prodrugs with E. coli purine nucleoside phosphorylase. Nucleosides Nucleotides 18, 745-757.
28. SHAH, A.C., BENOS, D.J., GILLESPIE, G.Y., and MARKERT, J.M. (2003). Oncolytic viruses: Clinical applications as vectors for the treatment of malignant gliomas. J. Neurooncol. 65, 203-226.
29. SHAPIRO, W.R., and SHAPIRO, J.R. (1998). Biology and treatment of malignant glioma. Oncology 12, 233-240.
30. SORSCHER, E.J., PENG, S., BEBOK, Z., ALLAN, P.W., BENNETT, Jr., L.L., and PARKER, W.B. (1994). Tumor cell bystander killing in colonie carcinoma utilizing the E. coli Deo D gene and generation of toxic purines. Gene Ther. 1, 233-238.
31. SOROCEANA, L., MANNING, Jr., T.J., and SONTHEIMER, H. (2001). Reduced expression of connexin-43 and functional gap junction coupling in human gliomas. Glia 33, 107-117.
32. VAN DER WAAIJ, D. (1968). Production of bacteria-free mice by antibiotic decontamination. In M. Miyakawa and T.D. Luckey, eds., Advances in Germfree Research and Gnotobiology. (CRC Press, Cleveland, OH) pp. 30-37.